Narrow search
Showing 1 - 3 of 3
Cover Image
Cost Effectiveness of Guanfacine Extended Release as an Adjunctive Therapy to a Stimulant Compared with Stimulant Monotherapy for the Treatment of Attention-Deficit Hyperactivity Disorder in Children and Adolescents
Sikirica, Vanja; Haim Erder, M.; Xie, Jipan; Macaulay, Dendy - In: PharmacoEconomics 30 (2012) 8, pp. 1-1
Background:Background: Attention-deficit hyperactivity disorder (ADHD) is a common psychiatric disorder in childhood, affecting 3-7% of school-age children in the US and imposing substantial economic burden. Stimulants are considered first-line pharmacological treatment and are the most...
Persistent link: https://www.econbiz.de/10010556689
Cover Image
Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany
Greven, Peter; Sikirica, Vanja; Chen, Yaozhu J.; … - In: The European journal of health economics : HEPAC ; … 18 (2017) 7, pp. 893-904
Persistent link: https://www.econbiz.de/10011869115
Cover Image
Estimation of Utilities in Attention-Deficit Hyperactivity Disorder for Economic Evaluations
Lloyd, Andrew; Hodgkins, Paul; Sasane, Rahul; Akehurst, Ron - In: The Patient: Patient-Centered Outcomes Research 4 (2011) 4, pp. 247-257
Background:Background: Attempts to estimate the cost effectiveness of attention-deficit hyperactivity disorder (ADHD) treatments in the past have relied on classifying ADHD patients as responders or non-responders to treatment. Responder status has been associated with a small gain in...
Persistent link: https://www.econbiz.de/10010614423